Approvals
  • Most Popular
  • Latest News
  • Breaking News
  • User Submitted Articles
  • Contribute an Article
  • GlobeNewswire
  • News and Analysis
  • About Us
  • Support
  • Bio-Path Holdings to Present at the Biotech Showcase™ 2014 Conference
    Monday, 06 January 2014 05:10
    Jan. 6, 2014 15:59 UTC

    Bio-Path Holdings to Present at the Biotech Showcase™ 2014 Conference

    Biotech Showcase 2014

    HOUSTON--(BUSINESS WIRE)-- Bio-Path Holdings, Inc. (OTCQX: BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive Officer, will present a company overview at the Biotech Showcase™ 2014 Conference in San Francisco, Calif., on Wednesday, January 15, 2014 at 8:00 a.m. Pacific Time.

    A webcast of Mr. Nielsen’s remarks will be available live. You can access the webcast at the Company’s website: www.biopathholdings.com.

    About Bio-Path Holdings, Inc.

    Bio-Path is a biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, Liposomal Grb-2, is in a Phase I study for blood cancers and in preclinical studies for triple negative and inflammatory breast cancers. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.

    Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Bio-Path’s ability to raise needed additional capital on a timely basis in order for it to continue its operations, have success in the clinical development of its technologies, the timing of enrollment and

    release of data in such clinical studies and

    Error. Page cannot be displayed. Please contact your service provider for more details. (9)

    the accuracy of such data, limited patient populations of early stage clinical studies and the possibility that results from later stage clinical trials with much larger patient populations may not be consistent with earlier stage clinical trials, and such other risks which are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q.
    These documents are available on request from Bio-Path Holdings or at www.sec.gov. Bio-Path disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    For more information, please visit the Company's website at http://www.biopathholdings.com.

    Contacts

    Bio-Path Holdings, Inc.
    Peter Nielsen, 832-971-6616
    President & Chief Executive Officer
    or
    Rx Communications Group, LLC
    Rhonda Chiger, 917-322-2569 (investors)
    rchiger@rxir.com


    Source: Bio-Path Holdings, Inc.




    BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

    Add this page to your favorite Social Bookmarking websites
    Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
     
    BMR:1